Young Tumor Infiltrating Lymphocytes (TIL)

BIOLOGICAL2 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Metastatic MelanomaMetastatic Ocular MelanomaMetastatic Uveal MelanomaSkin Cancer

Phase 2

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

TerminatedNCT01468818

National Cancer Institute (NCI)Metastatic Melanoma, Skin Cancer

Start: 2011-09-30End: 2013-08-31Updated: 2016-06-27

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

TerminatedNCT01814046

National Cancer Institute (NCI)Metastatic Ocular Melanoma, Metastatic Uveal Melanoma

Start: 2013-03-01End: 2017-05-31Updated: 2018-10-11

Related Papers

Phase 2 trial of TIL therapy for metastatic uveal melanoma: Evaluation of T cell potency and an in situ precision biomarker.

Journal of Clinical Oncology2026-05-27

Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.

2017-04-07213 citations